On track to become a leading European biotech
23 years of ground-breaking research and development with a first medicine on the market
10 year partnership signed with Gilead in 2019
An increasing global reach
Over 1300 employees globally
15 sites across Europe and the US
Innovative science to address patient needs is at the heart of our business
45% of employees work in R&D
31% of employees work in commercial
Our focus and commitment to patients will always remain at the center of everything we do with the aim to add years of life and quality of life of patients across the globe.
We are a fully integrated biotechnology company focused on discovering,developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan.
Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and …
We’re not only looking for scientists. We’re looking for pioneers in a wide range of domains: The best-in-class doctors, …
Our commitment to Corporate Social Responsibility (CSR) is intrinsically linked to our core mission: to discover and develop …